Nonsynonymous ATM mutations occur in approximately 11% of NSCLC samples and frequently co-occur with KRAS mutations, while showing mutual exclusivity with EGFR, TP53, and KEAP1 within the KRAS-mutant subset from clinicogenomic database (CGDB). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.